GLP-2 20MG
$356.00
GLP-2 is a groundbreaking synthetic peptide that mimics the action of two hormones, GLP-1 and GIP, to regulate blood sugar levels and promote weight loss. Known for its dual action, GLP-2 has gained attention for its effectiveness in managing type 2 diabetes and obesity. It enhances insulin sensitivity, reduces appetite, and supports weight loss, making it a vital component in both research and therapeutic applications focused on metabolic health and obesity management.
Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.
What Is GLP-2 20MG?
GLP-2 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for the treatment of type 2 diabetes in adults as an adjunct to diet and exercise, and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. GLP-2 works by mimicking the effects of two naturally occurring incretin hormones, GIP and GLP-1, which play crucial roles in glucose homeostasis and appetite regulation. This unique dual-action mechanism provides significant benefits in glycemic control and weight reduction.
Structure

Sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Molecular Formula: C221H342N46O68
Molecular Weight:4813.5 g/mol
CAS Number:2023788-19-2
Research Findings
- Glycemic Control: In clinical trials, GLP-2 demonstrated superior efficacy in reducing HbA1c levels compared to placebo and other diabetes medications, with a maximum reduction of 2.24% observed.
- Weight Loss: GLP-2 showed significant weight loss effects, with participants losing up to 22.5% of their initial body weight in clinical trials. In the SURMOUNT-1 trial, 36% of participants receiving the highest dose (15 mg) achieved ≥25% weight loss.
- Cardiometabolic Risk Factors: Treatment with GLP-2 resulted in improvements in various cardiometabolic measures, including blood pressure, fasting insulin levels, and lipid profiles.
- Prediabetes Reversal: At week 72 of the SURMOUNT-1 trial, 95.3% of participants with prediabetes at baseline who received GLP-2 reverted to normoglycemia, compared to 61.9% in the placebo group.
- Comparative Efficacy: GLP-2 demonstrated superior efficacy in both glycemic control and weight loss compared to selective GLP-1 receptor agonists like GLP-1 and dulaglutide.
Future Research Directions
- Cardiovascular Outcomes: Ongoing trials like SURPASS-CVOT aim to evaluate the long-term cardiovascular effects of GLP-2 in patients with type 2 diabetes.
- Expanded Indications: Research is underway to explore GLP-2's potential in treating conditions such as non-alcoholic steatohepatitis (NASH) and obesity-related heart failure with preserved ejection fraction.
- Combination Therapies: Future studies may investigate the potential synergistic effects of GLP-2 with other therapeutic agents for enhanced metabolic control.
- Long-term Safety: Extended studies are needed to evaluate the long-term safety profile of GLP-2, particularly in diverse patient populations.
- Mechanism of Action: Further research is required to fully elucidate the molecular mechanisms by which GLP-2 exerts its diverse effects, particularly the role of GIP receptor agonism.
References
-
Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. [Online].
Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 -
Drugs.com. (2024). GLP-2: Uses, Dosage, Side Effects & Warnings. [Online].
Available: https://www.drugs.com/tirzepatide.html -
Chavda, V.P., et al. (2022). GLP-2, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Frontiers in Pharmacology. [Online].
Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/ -
DrugBank. (2024). GLP-2: Uses, Interactions, Mechanism of Action. [Online].
Available: https://go.drugbank.com/drugs/DB15171 -
Jastreboff, A.M., et al. (2022). GLP-2 Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 -
ChemicalBook. (2024). GLP-2 | 2023788-19-2. [Online].
Available: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB24869395.htm
GLP-2 represents a significant advancement in the treatment of type 2 diabetes and obesity, offering superior efficacy in glycemic control and weight management compared to existing therapies. As with all novel medications, it is important to use GLP-2 under medical supervision, and its potential benefits and risks require ongoing evaluation through long-term clinical use and further research.